Stelara (Ustekinumab) Market Forecast and Analysis: Key Insights into Growth, Trends, and Emerging Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Growth Rate of the Stelara (Ustekinumab) Market Shape Industry Trends by 2034?
The market size for Stelara (ustekinumab) has seen significant enlargement in the past years. It is forecasted to expand from a value of $11,177.34 million in 2024 to achieve a worth of $11,850.79 million in 2025, reflecting a compound annual growth rate (CAGR) of 6.0%. The surge observed over the historic period is due to factors such as increased healthcare expenditure, the development of specialty drug delivery channels, the broadening of clinical trial programs, higher investments into research and development, and the growing utilization of telemedicine to provide greater treatment access.
Observe a robust expansion in the market size of stelara (ustekinumab) in the upcoming years, with an anticipated growth to $14,768.48 million by 2029, boasting a compound annual growth rate (CAGR) of 5.7%. This growth projection for the forecast period is powered by factors such as wider applications of stelara, the rising rates of autoimmune diseases, its high effectiveness in treating refractory cases when compared to other options, increased awareness among both patients and healthcare providers, and a heightened emphasis on personalized medicine. Key trends within this forecast period encompass the integration of biologic therapies, the creation of advanced drug delivery systems, the implementation of data-driven healthcare systems, collaborative partnerships and licensing agreements between pharmaceutical firms, and breakthroughs in biologics production technology.
Which Drivers Are Expected to Have the Greatest Impact on the Stelara (Ustekinumab) Market’s Growth?
An increase in the number of individuals suffering from psoriasis is predicted to drive the stelara (ustekinumab) market’s expansion. People with psoriasis, a long-term autoimmune disorder that speeds up skin cell turnover leading to red, scaly patches, are increasingly being diagnosed due to better medical techniques, environmental factors, genetic susceptibility, and an aging demographic. By targeting and restricting interleukin-12 and interleukin-23, stelara (ustekinumab) offers a valuable solution for psoriasis patients. It minimizes inflammation and plaque development effectively, promoting better skin health and managing long-term symptoms, thereby improving patient’s life quality. For example, a report from the National Library of Medicine, a US-based medical library released in May 2024, stated that psoriasis prevalence climbed to 0.221% in 2022, documenting 6,930 PsA incidents in a population of 3,133,500. As a result, the growing prevalence of psoriasis is anticipated to fuel the expansion of the stelara (ustekinumab) market.
Get Your Free Sample of the Global Stelara (Ustekinumab) Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp
Who Are the Key Market Players Influencing the Growth of the Stelara (Ustekinumab) Industry?
Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson
What Key Market Trends Are Shaping the Future of the Stelara (Ustekinumab) Industry?
A primary trend within the Stelara (Ustekinumab) market is the creation of innovative products such as biosimilars to Stelara, which serve as cost-effective treatment solutions for those suffering from chronic inflammatory illnesses. These Stelara biosimilars are biomedicines designed to mimic the therapeutic effects of Stelara (Ustekinumab) by targeting IL-12 and IL-23 to manage auto-immune diseases like psoriasis and psoriatic arthritis. For instance, Accord BioPharma Inc., an American biopharmaceutical corporation, announced in October 2024 that the U.S. Food and Drug Administration (FDA) approved IMULDOSA (ustekinumab-srlf), a Stelara (ustekinumab) biosimilar created by Johnson & Johnson. IMULDOSA is known for its wide applications in treating adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease and ulcerative colitis. It is also uniquely suitable for pediatric patients aged 6 years and above, suffering from moderate to severe plaque psoriasis and active psoriatic arthritis, demonstrating its versatility across different age brackets. This extensive applicability makes IMULDOSA a valuable choice for managing diverse immune-mediated inflammatory conditions.
Get Instant Access to the Global Stelara (Ustekinumab) Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-
What Are the Main Segments of the Stelara (Ustekinumab) Market, and How Are They Evolving?
The stelara (ustekinumab)market covered in this report is segmented –
1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Pediatric; Adult; Geriatric
Which Regions Are Emerging as Leaders in the Stelara (Ustekinumab) Market?
North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Defining Features of the Stelara (Ustekinumab) Market?
Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), key proteins involved in inflammatory and autoimmune responses. It is widely used to treat conditions such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Browse Through More Similar Reports By The Business Research Company:
Psoriasis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Radiosurgery And Radiotherapy Robotics Global Market Report 2025
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
